Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02670551 |
|
Recruitment Status :
Completed
First Posted : February 1, 2016
Results First Posted : January 30, 2019
Last Update Posted : January 30, 2019
|
Sponsor:
Forest Laboratories
Information provided by (Responsible Party):
Forest Laboratories
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 milligram (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Bipolar Disorder Depression | Drug: Cariprazine Drug: Placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 488 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression |
| Actual Study Start Date : | March 17, 2016 |
| Actual Primary Completion Date : | July 19, 2017 |
| Actual Study Completion Date : | July 19, 2017 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
|
Drug: Placebo |
|
Experimental: Cariprazine 1.5 mg
Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
|
Drug: Cariprazine
Other Name: VRAYLAR® |
|
Experimental: Cariprazine 3.0 mg
Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.
|
Drug: Cariprazine
Other Name: VRAYLAR® |
Primary Outcome Measures :
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Week 6 [ Time Frame: Baseline (Week 0) to Week 6 ]The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each of the 10 items was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement.
Secondary Outcome Measures :
- Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Week 6 [ Time Frame: Baseline (Week 0) to Week 6 ]The Clinical Global Impressions-Severity (CGI-S) is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of other participants the physician has observed. The participant was rated on a scale from 1 to 7, with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A negative change from Baseline indicates improvement.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for bipolar I disorder without psychotic features confirmed by the administration of the Mini International Neuropsychiatric Interview (MINI), with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration
- Currently treated as an outpatient at the time of enrollment
- A verified previous manic or mixed episode. Verification must include one of the following sources: --Treatment of mania with an anti-manic agent (eg, lithium or divalproate) or antipsychotic medication with an approved indication for mania --Hospital records/Medical records --Participant report corroborated by caretaker or previous or current treating clinician
- 17-item Hamilton Depression Rating Scale (HAMD-17) total score ≥ 20
- HAMD-17 item 1 score ≥ 2
- Clinical Global Impressions-Severity (CGI-S) score ≥ 4
- Negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test (women of childbearing potential only)
- Normal physical examination, clinical laboratory test results, and electrocardiogram (ECG) results or abnormal findings that are judged not clinically significant by the Principal Investigator (PI)
Exclusion Criteria:
- Young Mania Rating Scale (YMRS) total score > 12
- Four or more episodes of a mood disturbance (depression, mania, hypomania, or mixed state) within the 12 months before Visit 1
- Any current axis 1 psychiatric diagnosis other than bipolar disorder with the exception of specific phobias
-
History of meeting DSM-5 criteria for: ○ Dementia, amnesic, or other cognitive disorder ○ Schizophrenia, schizoaffective, or other psychotic disorder
○ Mental retardation - DSM-5-based diagnosis of borderline or antisocial personality disorder or other axis II disorder of sufficient severity to interfere with participation in this study
- History of meeting DSM-5 criteria for alcohol or substance abuse or dependence (other than nicotine or caffeine) within the 6 months before Visit 1
- Positive result on blood alcohol test or urine drug screen for any prohibited medication. Exception: ○ Participants with a positive cannabinoid on entry may be retested before randomization. If the participant remains positive, the participant is no longer eligible ○ Participants positive for opiates on entry, discussion with Study Physician is required.
- Electroconvulsive therapy in the 3 months before Visit 1
- Previous lack of response to electroconvulsive therapy
- Treatment with a depot antipsychotic drug within 1 treatment cycle before Visit 1
- Treatment with clozapine in a dose of > 50 mg/day in the past 2 years
- Prior participation in any investigational study of RGH-188 or cariprazine within the past 12 months
- Previous treatment with vagus nerve stimulation or transcranial magnetic stimulation within 6 months before Visit 1
- Prior participation with any clinical trials, involving experimental or investigational drugs, within 6 months before Visit 1 or during the study
- Initiation or termination of psychotherapy for depression within the 3 months preceding Visit 1, or plans to initiate, terminate, or change such therapy during the course of the study.
- Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
- Gastric bypass or any condition that would be expected to affect drug absorption (lap band procedures are acceptable if there is no problem with absorption)
- Known history of cataracts or retinal detachment
- Known human immunodeficiency virus infection
- Employee, or immediate relative of an employee, of the Sponsor, any of its affiliates or partners, or the study center
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02670551
Locations
Show 74 study locations
Sponsors and Collaborators
Forest Laboratories
Investigators
| Study Director: | Clincial Director | Forest Research Institute, Inc., an affiliate of Allergan, plc |
Study Documents (Full-Text)
Documents provided by Forest Laboratories:
Documents provided by Forest Laboratories:
Study Protocol [PDF] February 17, 2016
Statistical Analysis Plan [PDF] November 29, 2017
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Forest Laboratories |
| ClinicalTrials.gov Identifier: | NCT02670551 |
| Other Study ID Numbers: |
RGH-MD-54 2016-000757-13 ( EudraCT Number ) |
| First Posted: | February 1, 2016 Key Record Dates |
| Results First Posted: | January 30, 2019 |
| Last Update Posted: | January 30, 2019 |
| Last Verified: | January 2019 |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Bipolar Disorder Behavioral Symptoms Mood Disorders Mental Disorders Bipolar and Related Disorders |
Cariprazine Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs |